Estrella Immunopharma, Inc. (ESLAW) income statement
ESLAWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLA
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.06−0.00 (-2.08%)
Close on Nov 18, 2026Market cap $14.48MP/E –Yield –
Estrella Immunopharma, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2024
- -447.6%
Financial strength
- Current ratio
- 0.20
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1.1%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?